Prostacyclin synthase gene transfer accelerates reendothelialization and inhibits neointimal formation in rat carotid arteries after balloon injury

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 19, Issue 3, 1999, Pages 727-733

  Numaguchi, Yasushi ^a   Naruse, Keiji ^a   Harada, Mitsunori ^a   Osanai, Hiroyuki ^a   Mokuno, Shinji ^a   Murase, Kichiro ^a   Matsui, Hideo ^a   Toki, Yukio ^a   Ito, Takayuki ^a   Okumura, Kenji ^a   Hayakawa, Tetsuo ^a  

^a NAGOYA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Balloon injury; Gene therapy; Prostacyclin; Prostacyclin synthase; Restenosis

Indexed keywords

PROSTACYCLIN SYNTHASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY ENDOTHELIUM; ARTERY INJURY; ARTERY INTIMA; ARTICLE; BALLOON CATHETER; CAROTID ARTERY DISEASE; CONTROLLED STUDY; GENE TRANSFER; NONHUMAN; PRIORITY JOURNAL; PROSTAGLANDIN METABOLISM; RAT;

EID: 0344019469     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.19.3.727     Document Type: Article

References (54)

1. Landau C, Lange RA, Hills LD. Percutaneous transluminal coronary angioplasty. N Engl J Med. 1994;330:981-993.
2. Kastrati A, Schühlen H, Hausleiter J, Walter H, Zitzmann-Roth E, Schömig A. Restenosis after coronary stent placement and randomization to a four-week combined antiplatelet or anticoagulant therapy: six-month angiographic follow-up of the intracoronary stenting and antithrombotic regimen (ISAR) trial. Circulation. 1997;96:462-467.
3. Serruys PW, de Jaegere P, Kiemeneij F, Magaya C, Rutsch W, Heyndrickx G, Emanuelsson H, Marco J, Legrand V, Materne P, Belardi J, Sigwart U, Colombo A, Goy JJ, van den Heuvel P, Delcan J, Morel M-A. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. N Engl J Med. 1994;331:489-495.
4. Fischman DL, Leon MB, Baim DS, Schatz RA, Savage MP, Penn I, Detre K, Veltri L, Ricci D, Nobuyoshi M, Cleman M, Heuser R, Almond D, Teirstein PS, Fish D, Colombo A, Brinker J, Moses J, Shaknovich A, Hirshfeld J, Bailey S, Ellis S, Rake R, Goldberg S. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. N Engl J Med. 1994;331:496-501.
5. Franklin SM, Faxon DP. Pharmacologic prevention of restenosis after coronary angioplasty: review of the randomized clinical trials. Coron Artery Dis. 1993;4:232-242.
6. Herrman JP, Hermans WR, Vos J, Serruys PW. Pharmacological approaches to the prevention of restenosis following angioplasty. The search for the Holy Grail? (Part II). Drugs. 1993;46:249-262.
7. Nagler A, Miao H-Q, Aingorn H, Pines M, Genina O, Vlodavsky I. Inhibition of collagen synthesis, smooth muscle cell proliferation, and injury-induced intimal hyperplasia by halofuginone. Atheroscler Thromb. 1997;17:194-202.
8. Matsuno H, Kozawa O, Niwa M, Uematsu T. Inhibition of von Willebrand factor binding to platelet GPIb by a fractionated aurintricarboxylic acid prevents restenosis after vascular injury in hamster carotid artery. Circulation. 1997;96:1299-1304.
9. The CAVEAT Study Group. A comparison of directional coronary athrectomy with coronary angioplasty in patients with coronary artery disease. N Engl J Med. 1993;329:221-227.
10. Teirstein PS, Warth DC, Haq N, Jenkins NS. McCowan LC, Aubanel-Reidel P, Morris N, Ginsburg R. High speed rotational coronary atherectomy for patients with diffuse coronary artery disease. J Am Coll Cardiol. 1991;18:1694-1701.
11. Teirstein PS, Massullo V, Jani S, Popma JJ, Mintz GS, Russo RJ, Schatz RA, Guarneri EM, Steuterman S, Morris NB, Leon MB, Tripuraneni P. Catheter-based radiotherapy to inhibit restenosis after coronary stenting. N Engl J Med. 1997;336:1697-1703.
12. Chang MW, Barr E, Seltzer J, Jian Y-Q, Nabel GJ, Nabel EG, Pharmacek MS, Leiden JM. Cytostatic gene therapy for vascular proliferative disorders with a constitutively active form of the retinoblastoma gene product. Science. 1995;267:518-522.
13. Chang MW, Barr E, Lu MM, Barton K, Leiden JM. Adenovirus-mediated overexpression of the cyclin/cyclin-dependent kinase inhibitor, p21, inhibits vascular smooth muscle cell proliferation and neointima formation in the rat carotid artery model of balloon angioplasty. J Clin Invest. 1995;95:2260-2268.
14. Forough R, Koyama N, Hasenstab D, Lea H, Clowes M, Nikkari ST, Clowes AW. Overexpresion of tissue inhibitor of matrix metalloproteinase-1 inhibits vascular smooth muscle cell functions in vitro and in vivo. Circ Res. 1996;79:812-820.
15. George SJ, Johnson JL, Angelini GD, Newby AC, Baker AH. Adenovirus-mediated gene transfer of the human TIMP-1 gene inhibits smooth muscle cell migration and neointimal formation in human saphenous vein. Hum Gene Ther. 1998;9:867-877.
16. Guzman RJ, Hirschowitz EA, Brody SL, Crystal RG, Epstein SE, Finkel T. In vivo suppression of injury-induced vascular smooth muscle cell accumulation using adenovirus-mediated transfer of the herpes simplex virus thymidine kinase gene. Proc Natl Acad Sci U S A. 1994;91: 10732-10736.
17. Mullen CA, Kilstrup M, Blaese RM. Transfer of the bacterial gene for cytosine deaminase to mammalian cells confers lethal sensitivity to 5-fluorocytosine: a negative selection system. Proc Natl Acad Sci U S A. 1992;89:33-37.
18. Rade JJ, Schulick AH, Virmani R, Dichek DA. Local adenoviral-mediated expression of recombinant hirudin reduces neointimal formation after arterial injury. Nat Med. 1996;2:293-398.
19. Ueno H, Haruno A, Morisaki N, Furuya M, Kanagawa K, Takeshita A, Saito Y. Local expression of c-type natriuretic peptide markedly supresses neointimal formation in rat injured arteries through an autocrine/paracrine loop. Circulation. 1997;96:2272-2279.
20. von der Leyden HE, Gibbons GH, Morishita R, Lewis NP, Zhang L, Nakajima M, Kaneda Y, Cooke JP, Dzau VJ. Gene therapy inhibiting neointimal vascular lesion: in vivo transfer of endothelial cell nitric oxide synthase gene. Proc Natl Acad Sci U S A. 1995;92:1137-1141.
21. Janssens S, Flaherty D, Nong Z, Varenne O, van Pelt R, Haustemans C, Zoldhelyi P, Gerard R, Collen D. Human endothelial nitric oxide synthase gene transfer inhibits vascular smooth muscle cell proliferation and neointima formation after balloon injury in rats. Circulation. 1998;97: 1274-1281.
22. Zoldhelyi P, McNatt J, Xu X-M, Loose-Mitchell D, Meidell RS, Clubb FJ Jr, Buja LM, Willerson JT, Wu KK. Prevention of arterial thrombosis by adenovirus-mediated transfer of cyclooxygenase gene. Circulation. 1996; 93:10-17.
23. Asahara T, Bauters C, Pastore C, Kearney M, Rossow S, Bunting S, Ferrara N, Symes JF, Isner JM. Local delivery of vascular endothelial growth factor accelerates reendothelialization and attenuates intimal hyperplasia in balloon-injured rat carotid artery. Circulation. 1995;91: 2793-2801.
24. 2 and prostacyclin. Pharmacol Rev. 1979;30:293-331.
25. Furchgott RF, Zawadzki JV. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature. 1980;299: 373-376.
26. Lam JYT, Chesebro JH, Badimon L, Fuster V. Exogenous prostacyclin decreases vasoconstriction but not platelet thrombus deposition after arterial injury. J Am Coll Cardiol. 1993;21:488-492.
27. 2 on platelet aggregation in different species. Prostaglandins. 1978;16:373-387.
28. Jones DA, Benjamin CW, Linseman DA. Activation of thromboxane and prostacyclin receptors elicits opposing effects on vascular smooth muscle cell growth and mitogen-activated protein kinase signaling cascades. Mol Pharmacol. 1995;48:890-896.
29. 2 analogue) in the atherosclerotic rabbit artery after angioplasty. J Cardiovasc Pharmacol. 1995;25:947-952.
30. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature. 1993;362:801-809.
31. Gibbons GH, Dzau VJ. The emerging concept of vascular remodeling. N Engl J Med. 1994;330:1431-1438.
32. Van Belle E, Bauters C, Asahara T, Isner JM. Endothelial regrowth after arterial injury: from vascular repair to therapeutics. Cardiovasc Res. 1998;38:54-68.
33. Baek S, March KL. Gene therapy for restenosis-Getting nearer the heart of the matter. Circ Res. 1998;82:295-305.
34. DeYoung MB, Dichek DA. Gene therapy for restenosis-Are we ready? Circ Res. 1998;82:306-313.
35. Tone Y, Inoue H, Hara S, Yokoyama C, Hatae T, Oida H, Narumiya S, Shigemoto R, Yukawa S, Tanabe T. The regional distribution and cellular localization of mRNA encoding rat prostacyclin synthase. Eur J Cell Biol. 1997;72:268-277.
36. Chomczinski P, Sacchi N. Single step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem. 1978;162:156-159.
37. 2 expression by uni-axial cyclic stretch in human lung fibroblast cells. Biochem Biophys Res Commun. 1998;244:615-619.
38. Miano JM, Tola RR, Vlasic N, Danishefsky KJ, Stemerman MB. Early proto-oncogene expression in rat aortic smooth muscle cells following endothelial removal. Am J Pathol. 1990;137:761-765.
39. Libby P, Schwartz D, Brogi E, Tanaka H, Clinton SK. A cascade model for restenosis - A special case of atherosclerosis progression. Circulation. 1992;86(suppl III):47-52.
40. 2) to inhibit platelet aggregation and to prevent restenosis after coronary angioplasty: results of a randomised placebo controlled trial. Br Heart J. 1994;71:7-15.
41. The Primary Pulmonary Hypertension Study Group. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med. 1996;334: 296-302.
42. Jones DK, Higenbottam TW, Wallwork J. Treatment of primary pulmonary hypertension with intravenous epoprostenol (prostacyclin). Br Heart J. 1987;57:270-278.
43. Barst RJ, Rubin LJ, McGoon MD, Caldwell EJ, Long WA, Levy PS. Survival in pulmonary hypertension with long-term continuous intravenous prostacyclin. Ann Intern Med. 1994;121:409-415.
44. Vanhoutte PM. Endothelium-dependent contractions in arteries and veins. Blood Vessels. 1987;24:141-144.
45. 2 may be the endothelium-derived contracting factor released by acetylcholine in the aorta of the rat. Hypertension. 1990;15:475-481.
46. 2 as an endothelium-derived contracting factor and its interaction with endothelium-derived nitric oxide. J Hypertens. 1991;9:729-736.
47. Pritchard KA Jr, O'Banion MK, Miano JM, Vlasic N. Bhatia UG, Young DA, Stemerman MB. Induction of cyclooxygenase-2 in rat vascular smooth muscle cells in vitro and in vivo. J Biol Chem. 1994;269: 8504-8509.
48. Shitashige M, Morita I, Murota S. Different substrate utilization between prostaglandin endoperoxidase H synthase-1 and -2 in NIH3T3 fibroblasts. Biochim Biophys Acta. 1998;1389:57-66.
49. Lüscher TF. Imbalance of endothelium-derived relaxing and contracting factors: a new concept in hypertension? Am J Hypertens. 1990;3: 317-330.
50. Smith JG, Walzern RL, German JB. Liposomes as agents of DNA transfer. Biochim Biophys Acta. 1993;1154:327-340.
51. Ohno T, Gordon D, San H, Pompili VJ, Imperiale MJ, Nabel GJ, Nabel EG. Gene therapy for vascular smooth muscle cell proliferation after arterial injury. Science. 1994;265:781-784.
52. O'Brien ER, Alpers CE, Stewart DK, Ferguson M, Tran N, Gordon D, Benditt EP, Hinohara T, Simpson JB, Schwartz SM. Proliferation in primary and restenotic coronary atherectomy tissue. Implications for antiproliferative therapy. Circ Res. 1993;73:223-231.
53. Mintz GS, Popma JJ, Pichard AD, Kent KM, Satler LF, Wong C, Hong MK, Kovach JA, Leon MB. Arterial remodeling after coronary angioplasty: a serial intravascular ultrasound study. Circulation. 1996;94: 35-43.
54. de Smet BJGL, Pasterkamp G, van der Helm Y, Borst C, Post MJ. The relation between de novo atherosclerosis remodeling and angioplasty-induced remodeling in an atherosclerotic Yukatan micropig model. Arterioscler Thromb Vasc Biol. 1998;18:702-707.